Investor Relations

Investor Overview

KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

 

Stock Quote
KMPH (Common Stock)
PriceChange% ChangeVolume
$3.350.000.00%11,370
Previous CloseToday's OpenIntraday HighIntraday Low
$3.35$3.40$3.40$3.30
Exchange: NASDAQ (US Dollar)
01/17/17 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
01/09/17
KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain
01/04/17
KemPharm to Present at Biotech Showcase 2017
12/20/16
KemPharm Granted "Fast Track" Designation for KP201/IR
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources